Spyre Therapeutics, Inc. SYRE Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $85.72M-4.1% | $89.42M-52.7% | $189.22M+420% | $36.42M+114% | ||
| $670.81M+30.6% | $513.67M+242% | $150.38M+621% | $20.85M-73.3% | ||
| $21.25M+295% | $5.39M+139% | $2.25M-63.5% | $6.17M+24.7% | ||
| $440.9M+30.3% | $338.44M+192% | $115.78M+455% | $20.85M— | ||
| $26.68M— | —— | —— | —— | ||
| $777.78M+27.8% | $608.47M+78.2% | $341.53M+449% | $62.26M-37.0% | ||
| $777.78M+27.8% | $608.48M+78.0% | $341.86M+381% | $71.14M-35.3% | ||
| $26.95M-2.8% | $27.71M+111% | $13.11M+2.1% | $12.84M-8.5% | ||
| $7.94M+39.6% | $5.69M+40.3% | $4.05M-11.7% | $4.59M— | ||
| $58.69M+8.6% | $54.06M+69.1% | $31.98M+118% | $14.66M-27.2% | ||
| $0— | —— | —— | $0-100% | ||
| $26.68M-70.6% | $90.68M+23.7% | $73.29M+252% | $20.84M-19.8% | ||
| 400M+3,076,823% | 13K+30.0% | 10K+66.7% | 6K+20.0% | ||
| $1.69B+26.4% | $1.33B+74.8% | $763.19M+60.3% | $475.97M+11.8% | ||
| -$1.13B-16.0% | -$972.43M-27.2% | -$764.41M-79.6% | -$425.62M-24.5% | ||
| $869K+383% | $180K-40.4% | $302K+729% | -$48K-140% | ||
| $715.24M+38.1% | $517.8M+181% | $184.02M+266% | $50.31M-40.1% | ||
| $777.78M+27.8% | $608.48M+78.0% | $341.86M+381% | $71.14M-35.3% | ||
| $669.94M+30.5% | $513.51M+242% | $150.1M+619% | $20.88M— | ||
| $0— | $0— | $0— | $0— | ||
| $0— | $0— | $0— | $0— | ||
| $180.96M-27.4% | $249.26M+1,591% | $14.74M-41.4% | $25.17M— | ||
| $180.96M-27.4% | $249.26M+1,591% | $14.74M-41.4% | $25.17M— | ||
| $116K-76.5% | $493K+49,200% | $1K-97.1% | $34K— | ||
| $0— | $0— | $0— | $0— | ||
| $180.96M-27.4% | $249.26M+1,591% | $14.74M-41.4% | $25.17M— | ||
| $180.96M-27.4% | $249.26M+1,591% | $14.74M-41.4% | $25.17M— | ||
| $180.96M-27.4% | $249.26M+1,591% | $14.74M-41.4% | $25.17M— | ||
| $670.81M+30.6% | $513.67M+242% | $150.38M+621% | $20.85M-73.3% | ||
| —— | —— | —— | —— | ||
| $669.94M+30.5% | $513.51M+242% | $150.1M+619% | $20.88M— | ||
| $22.82M-9.0% | $25.08M+1,704% | $1.39M— | $0— | ||
| $22.82M-9.0% | $25.08M+1,704% | $1.39M— | $0— | ||
| $1.4M+112% | $661K-55.2% | $1.47M+55.8% | $946K— | ||
| $3.86M-89.5% | $36.62M-11.4% | $41.31M— | $0— | ||
| $26.95M-2.8% | $27.71M+111% | $13.11M+2.1% | $12.84M-8.5% | ||
| $0— | $0— | $0— | $0— | ||
| $0.000.0% | $0.000.0% | $0.000.0% | $0.00— | ||
| 78.2M+29.8% | 60.3M+67.1% | 36.1M+1,279% | 2.6M— | ||
| $1.69B+26.4% | $1.33B+74.8% | $763.19M+60.3% | $475.97M+11.8% | ||
| $15K+15.4% | $13K+30.0% | $10K+66.7% | $6K+20.0% | ||
| $180.96M-27.4% | $249.26M+1,591% | $14.74M-41.4% | $25.17M— | ||
| $986K+51.5% | $651K+129% | $284K+14,100% | $2K— | ||
| $116K-76.5% | $493K+49,200% | $1K-96.8% | $31K— | ||
| $669.94M+30.5% | $513.51M+242% | $150.1M+619% | $20.88M— | ||
| $26.68M— | —— | —— | —— | ||
| $17.42M-16.5% | $20.86M+194% | $7.09M— | —— | ||
| $1.4M+112% | $661K-55.2% | $1.47M+55.8% | $946K— | ||
| $116K-76.5% | $493K+49,200% | $1K-96.8% | $31K— | ||
| $986K+51.5% | $651K+129% | $284K+14,100% | $2K— | ||
| $669.94M+30.5% | $513.51M+242% | $150.1M+619% | $20.88M— | ||
| $440.9M+30.3% | $338.44M+192% | $115.78M+455% | $20.85M— | ||
| $0-100% | $6K0.0% | $6K— | —— | ||
| $0— | $0— | $0— | —— | ||
| $00.0% | $00.0% | $00.0% | $0— | ||
| $400M0.0% | $400M0.0% | $400M+1,900% | $20M— | ||
| $78.19M+29.8% | $60.26M+67.1% | $36.06M+1,279% | $2.61M— | ||
| $78.19M+29.8% | $60.26M+67.1% | $36.06M+1,279% | $2.61M— | ||
| $0— | $0— | $0— | $0— | ||
| $180.96M-27.4% | $249.26M+1,591% | $14.74M-41.4% | $25.17M— | ||
| $0— | $0— | $0— | $0— | ||
| $116K-76.5% | $493K+49,200% | $1K-97.1% | $34K— | ||
| $229.92M+31.2% | $175.22M+406% | $34.6M— | —— | ||
| $116K-76.5% | $493K+49,200% | $1K-97.1% | $34K— | ||
| $180.96M-27.4% | $249.26M+1,591% | $14.74M-41.4% | $25.17M— | ||
| $26.68M— | —— | —— | —— | ||
| $3.86M-89.5% | $36.62M-11.4% | $41.31M— | $0— | ||
| —— | —— | —— | —— | ||
| $179K-64.3% | $501K+2.7% | $488K+47.9% | $330K— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Spyre Therapeutics, Inc.'s total assets?
- Spyre Therapeutics, Inc. (SYRE) holds $764.0M in total assets, up 34.1% year over year.
- How much cash does Spyre Therapeutics, Inc. have?
- Spyre Therapeutics, Inc. holds $97.2M in cash and equivalents.
- Can Spyre Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 8.97 — current assets exceed current liabilities.
- Where does Spyre Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.